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Abstract
Background: The hypomania checklist-32 (HCL-32) is a widely used questionnaire developed for identifying
hypomanic components in patients with a depressive episode. Measuring and screening previous hypomanic
symptoms in individuals without any definite history of depressive episode would also be needed for early
detection of bipolar disorders (BDs). This study aimed at testing the clinical utility of the HCL-32 for screening of
BDs in the non-clinical population.
Methods: Lifetime history of hypomanic symptoms was evaluated by using the HCL-32 in 220 patients with BDs
and 313 non-clinical individuals. Sensitivity, specificity, and the area under the curve (AUC) of the Receiver
Operating Characteristic (ROC) were evaluated for assessing the discriminatory power of the scale and its two
sub-domains in screening BDs.
Results: The mean HCL-32 total score was significantly higher in the Bipolar II disorder group compared to the
non-clinical group (P < 0.001). Most of the items (10/12) of the irritable/risk-taking factor showed higher positive
responses in patient groups. Items of active/elated factor showed mixed results. The HCL-32 total score and the
active/elated factor score were not adequate for both BDs and its subgroups with AUC values of less than 0.7. The
irritable/risk-taking factor score showed higher discrimination power, i.e. AUC for BDs, Bipolar I disorder, and Bipolar
II disorder was 0.71, 0.67, and 0.75, respectively.
Conclusions: The HCL-32 could not adequately distinguish BD patients from the non-clinical adult population.
However, the current study identified items of irritable/risk-taking factor of the scale that could be useful in
screening BDs in the general population.
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Background
It is well known that assessing previous incidents of
hypomania requires special attention and caution in
psychiatric practice [1]. Individuals do not always perceive
hypomania as pathological, and as such do not spontan-
eously report it to clinicians [2]. Therefore, the recognition
of hypomania is frequently delayed, distorting the accurate
identification of diagnosis [3]. Individuals with bipolar dis-
order (BD) often report that the illness manifested itself
early in their life, but accurate diagnosis lagged by many
years [4]. Failure to diagnose or misdiagnosis in BD is a
significant clinical and public health problem, as it brings
about delayed intervention and an unfavorable treatment
outcome.
The need to improve the recognition and diagnosis of
hypomania has led to the development of self-report
questionnaires for bipolar disorder, including the Mood
Disorder Questionnaire (MDQ) [5], and the Hypomania
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Checklist (HCL-32) [6]. The HCL-32 is a self-report
questionnaire developed to identify hypomanic compo-
nents in patients with major depressive episodes [6]. It
has been used as a screening instrument for BDs and bi-
polar spectrum disorders in various psychiatric clinical
settings [7]. The HCL-32 showed an adequate discrimin-
ation power for distinguishing individuals with BDs from
those with major depressive disorders in previous studies
[6–9]. Those studies also identified two or three sub-
domains of the scale representing separate clinical
factors. Compared to the MDQ, the HCL-32 showed
higher sensitivity and lower specificity in screening
hypomania, having high accuracy for the detection of
‘softer’ BD cases [10]. However, both questionnaires
were developed for and have been applied to patients
in a depressive episode.
Even though a manic/hypomanic episode is usually
preceded by one or more depressive episodes, the po-
larity of the first episode of illness in BDs is manic
(or hypomanic) in at least one third of patients [11, 12].
Untreated hypomania may be associated with marital,
financial, legal, occupational and other psychosocial
problems [13]. Therefore, screening previous and current
hypomanic symptoms in individuals without any clear
depressive episode would also be important for early
detection and adequate treatment of BDs.
The aim of the current study was to test the clinical
utility of the HCL-32 for the screening of BDs in the
non-clinical adult population. Considering that bipolar
I disorder (BD1) and bipolar II disorder (BD2) might
have somewhat discrete clinical natures, and that the
development of the HCL-32 was originally more focused
on BD2 than BD1 [6], the same analyses were performed
separately for these two diagnoses. Additionally, we




We used patients’ data from the HCL-32 included in the
comprehensive psychological test that has been applied
to outpatients and inpatients of the Samsung Medical
Center. Patients had been consecutively referred by their
attending psychiatrists for psychological evaluation from
March 2006 to September 2010. Among these patients,
we selected patients who met the diagnostic criteria of
the Diagnostic and Statistical Manual of Mental Disor-
ders, 4th edition (DSM-IV) BD1 and BD2 as the study
subjects. Clinical diagnosis was made by the attending
psychiatrist of each patient. Additionally an independent
diagnosis with a structured clinical interview using the
Korean version of the Structured Clinical Interview of
DSM-IV [14] or the Korean version of the Mini Inter-
national Neuropsychiatric Interview [15] was made by a
well-trained psychologist. The exclusion criteria were 1)
patients whose clinical diagnosis and diagnosis by a
structured interview were not consistent, 2) patients in
unstable or severe clinical status who could not cooper-
ate with the study procedures, and 3) individuals who
were illiterate, suffering from mental retardation, de-
mentia or intellectual impairment. We received written
consent from the subjects for the use of their psycho-
logical test data from clinical researches of Samsung
Medical Center. Finally, data of 112 patients with BD1
and 108 patients with BD2 were included in the ana-
lyses. The sample included 145 (65.9 %) inpatients and
75 (34.1 %) outpatients. The patients’ most recent epi-
sode was as follows: manic, 65 (12.1 %); hypomanic, 11
(2.1 %); mixed, 16 (3.0 %); depressed, 16 (3.0 %); and un-
specified, 4 (0.8 %). Only ten patients were in remission
at the time of psychological assessment. Healthy subjects
between 18 and 60 years of age were recruited from the
local community from February to June in 2012 as a
control group for the BD studies of our research group.
Detailed descriptions on the control group were also
presented in a previous paper from our group [16]. Indi-
viduals with any history of psychiatric illness, including
any mood episode, mental retardation, substance abuse,
or medical illness and medications known to affect
moods were excluded [16], and data of 313 individuals
were included in the current analysis. Written informed
consent was obtained from all participants for the use of
their test data in the BD studies of our research group.
This study was approved by the Institutional Review
Board of the Samsung Medical Center.
Measures
Application of the Hypomania Checklist (HCL-32)
The HCL-32 comprises 32 “yes” or “no” questions on
hypomanic symptoms appearing in emotions, behaviors,
or thoughts. Participants are requested to remember ‘a
period when you were in a “high” state’ and to indicate if
specific behaviors, thoughts, or emotions were present
in such a state. The total score is the number of items with
a “yes” response. Two sub-domains have been consistently
identified through previous studies, i.e. active/elated and
irritable/risk-taking factors [6, 17–19]. Classification
of individuals to the sub-domains that show minor differ-
ences among studies was conducted according to the sub-
domain structure of the large-scale transcultural study of
Angst et al. [17]. We used the validated Korean version of
the HCL-32 [20, 21].
Analysis
Differences in demographic characteristics between pa-
tient groups and the control group were evaluated using
the analysis of variance (ANOVA) for continuous vari-
ables and the χ2 test for dichotomous variables. The area
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under the curves (AUC) of the receiver operating char-
acteristic (ROC) curves were evaluated to determine the
discriminatory power of the HCL-32 and its sub-
domains in screening BD. The score with the highest
combination of sensitivity and specificity (Youden's
index) was determined as the optimal cut-off score [22].
The overall performance was expressed by the area
under the ROC curve (AUC), defining performances as
follows: excellent (0.90–1.00), good (0.80–0.89), fair
(0.70–0.79), poor (0.60–0.69) or very poor (<0.60) [23].
The positive predictive value (PPV) was calculated by
dividing the number of true positives by the number of
true positives plus false positives. Negative predictive
value (NPV) was calculated by dividing the number of
true negatives by the number of true negatives plus false
negatives.
IBM SPSS 20.0 (IBM corp., Armonk, NY, USA) and R
3.0.2 (R Development Core Team, Vienna, Austria,
http://www.R-project.org/) with pROC [24] and qvalue
[25] packages was used for statistical analyses. P value <
0.05 was considered as statistically significant. Analysis
of false discovery rate (FDR) [26] was applied to control
for experiment-wise type I errors resulting from multiple
comparisons. The FDR procedure controls for the ex-
pected proportion of false discoveries (i.e. incorrectly
rejected null hypotheses) by providing an adjusted over-
all q-value, with adjusted p-values for each comparison.
The FDR threshold was set to 0.05.
Results
The demographic and clinical characteristics of the
subjects are presented in Table 1. There was no significant
difference in age and sex among subject groups. Educa-
tional level was significantly higher in the control group
compared to patient group (P < 0.001).
Patient groups showed higher HCL-32 total score
compared to the control group. However, a statistically
significant difference was observed only between the BD2
group and the control group (P < 0.001). For the active/
elated factor score, there was no significant difference
among subject groups (P = 0.307). Irritable/risk-taking
score was highest in the BD2 group and there was a
significant difference among groups (P < 0.001, control <
BD1 < BD2). The positive response rate of each item is
presented in Table 2. Ten of 12 items (83.3 %) of the “irrit-
able/risk-taking” factor showed a higher positive response
rate in patient groups compared to the control group.
Among the 19 items of active/elated factor, 13 items
(68.4 %) showed no group difference, and 3 items revealed
a significantly higher positive response rate in the control
group compared to BD1.
The AUC of the ROC curve and optimal cut-off scores
of the HCL-32 and 2 sub-domains for discriminating
patients groups from the control group are summa-
rized in Table 3. The AUC range was between 0.51
and 0.75. An AUC of 0.7 or higher was observed only
in the irritable/risk-taking factor for discriminating
BD and BD2 from the control group. The specificity
and sensitivity for screening BD at the optimal cut-off
score are also presented in Table 3. The HCL-32 total
score showed high specificity (0.82–0.93) and poor
sensitivity (0.31–0.36). The irritable/risk-taking factor
score had acceptable ranges of specificity (0.62) and
sensitivity (0.65–0.74).
Discussion
This study investigated the clinical utility of the HCL-32
for screening BDs in the non-clinical general population.
The HCL-32 total score and active/elated factor score
did not have adequate screening properties to differenti-
ate patient groups from the control group. However, the
irritable/risk-taking factor score with an AUC range of
0.67–0.75 was better able to differentiate between the
two groups.
Table 1 Sociodemographic and clinical characteristics of the subjects (n = 533)
Control (n = 313) BD1 (n = 112) BD2 (n = 108) Statistics (F or χ2) P-value Post hoc
Age, years (mean ± SD) 33.5 ± 9.2 33.9 ± 1.3 35.0 ± 1.3 0.0734 0.481
Sex 3.766 0.15
Male 122 (39.0 %) 39 (34.8 %) 31 (28.7 %)
Female 191 (61.0 %) 73 (65.2 %) 77 (71.3 %)
Education, n (%) 36.162 <0.001 Control > BD1, BD2
College graduate or more 254 (81.1 %) 65 (58.6 %) 61 (56.6 %)
Hypomania scores (mean ± SD)
HCL-32 total 14.7 ± 5.4 16.1 ± 6.7 17.6 ± 6.5 10.527 <0.001 BD2 > Control
Active/elated 12.4 ± 4.7 11.9 ± 5.0 13.0 ± 4.9 1.401 0.247
Irritable/risk-taking 2.2 ± 1.8 3.9 ± 3.0 4.5 ± 2.8 49.280 <0.001 BD2, BD1 > Control
Post hoc: Scheffe’s test for continuous measures, pair-wise chi-square test for categorical measures
BD1 bipolar I disorder, BD2 bipolar II disorder, HCL-32 hypomania checklist 32
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Demographically, female dominance was observed in
both the patient group and the control group and had
no significant difference among groups. According to a
systematic review of prevalence studies, the mean preva-
lence rate of BDs for males and females was 0.625 %
(SD: 0.679) and 0.968 % (SD: 0.945), respectively [27].
Another review of the prevalence of BDs in general
primary care samples also reported higher prevalence in
females [28]. Female dominance has been observed fre-
quently in clinical studies that recruited consecutive
cases of BD patients [29, 30]. Regarding education, the
control group was biased to higher educational level,
which might affect the positive response rate of their
previous mood experiences.
The scores for the patients groups in the current study
(16.1 for BD1, and 17.6 for BD2) were similar to those of
the initial report of Angst et al. [6] (18.2 for BD1, and
17.3 for BD2) and other previous studies, i.e., 15.4–18.8
for BD1, and 17.3–18.1 for BD2 [9, 21]. The mean HCL-
32 total score of the control group in the current study
Table 2 Comparison of positive response rate of HCL-32 items among the subjects groups
Positive response (%) χ2 P value post-hoc
Control (n = 313) BD1 (n = 112) BD2 (n = 108) normal FDR
Active/elated factor
1 need less sleep 53.0 53.6 63.0 3.344 0.188 0.27
2 more energetic 79.6 75.9 84.3 2.398 0.301 0.42
3 more self-confident 77.9 78.6 77.8 0.027 0.987 0.97
4 enjoy my work more 78.6 73.2 77.8 1.378 0.502 0.61
5 more sociable 70.6 67.9 70.4 0.307 0.858 0.93
6 want to travel more 59.7 43.8 49.1 9.947 0.007 0.02 Control > BD1
10 physically more active 52.9 48.6 55.1 0.977 0.613 0.69
11 plan more activities 77.6 64.3 83.3 12.064 0.002 0.01 BD2, Control > BD1
12 have more ideas/creative 65.5 72.3 67.6 1.752 0.417 0.53
13 less shy 62.3 70.4 70.1 3.552 0.169 0.26
14 wear more extravagant clothes 37.4 41.4 54.2 9.292 0.01 0.02 BD2 > Control
15 meet more people 61.9 57.7 57.0 1.102 0.576 0.67
16 more interested in sex 30.8 34.8 45.8 7.945 0.019 0.04 BD2 > Control
18 talk more 64.9 71.4 79.4 8.291 0.016 0.03 BD2 > Control
19 think faster 66.1 65.8 73.1 1.988 0.37 0.49
20 make more jokes 73.8 60.4 70.4 7.091 0.029 0.05
22 engage in more new things 77.6 75.9 75.9 0.199 0.905 0.95
24 do more quickly/easily 68.4 68.5 69.4 0.044 0.978 0.97
28 mood higher, more optimistic 80.8 67.6 71.3 9.672 0.008 0.02 Control > BD1
Irritable/risk-taking factor
7 drive faster 10.0 21.6 27.9 21.993 <0.001 <0.01 BD1, BD2 > Control
8 spend more 39.3 48.2 61.1 15.796 <0.001 <0.01 BD2 > Control
9 take more risks 9.3 25.9 34.6 41.081 <0.001 <0.01 BD1, BD2 > Control
21 more easily distracted 29.7 40.2 48.6 13.619 0.001 <0.01 BD2 > Control
23 thoughts jump 45.4 60.7 65.4 16.58 <0.001 <0.01 BD1, BD2 > Control
25 more impatient/irritable 14.7 44.1 40.2 50.986 <0.001 <0.01 BD1, BD2 > Control
26 can be exhausting or irritating 5.1 32.4 27.1 61.865 <0.001 <0.01 BD1, BD2 > Control
27 get into more quarrels 2.9 24.3 23.4 55.664 <0.001 <0.01 BD1, BD2 > Control
29 drink more coffee 30.7 31.5 41.1 4.07 0.131 0.21
30 smoke more cigarettes 5.8 22.7 23.8 34.864 <0.001 <0.01 BD1, BD2 > Control
31 drink more alcohol 23.0 22.5 33.0 4.673 0.097 0.16
32 take more drugs 0.6 24.1 14.2 65.772 <0.001 <0.01 BD1, BD2 > Control
BD1 bipolar I disorder, BD2 bipolar II disorder, FDR false discovery rate, Post hoc Pair-wise chi-square test
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(14.7) was similar to those of previous studies, i.e., 15.8
[31] and 15.7 [19]. However, the HCL-32 total score of
the control group was higher than that of depression pa-
tients in previous studies, i.e., 7.9–14.5 [6, 8, 9, 32, 33].
As a result, the cut-off scores of the HCL-32 yielding the
best combination of sensitivity and specificity for screen-
ing BDs in the present study (19–21) were higher than
the cut-off score of 14 that has been accepted as optimal
for discriminating BDs from MDD in previous studies
[6, 8, 32, 34]. In analyzing individual items, high HCL-32
total scores of the control group resulted from a high
positive response rate (30.8 % ~ 80.8 %) to items of ac-
tive/elated factor. This result might indicate that normal
persons are more likely to report their experience of
positive or high mood state than depressive patients.
The majority of items of irritable/risk-taking factor
showed a higher response rate in patient groups in con-
trast to non-specific high positive response to items of
active/elated factor. This phenomenon is indicated by
the much better discrimination properties (AUC and
sensitivity and specificity at optimal cut-off score) of the
risk-taking/irritable factor score compared to the HCL-
total score and active/elated factor score. These results
are consistent with results of a previous study by Meyer
et al. in which German people with probable episodes of
hypomania showed a higher score only in the ‘risk-tak-
ing/irritable’ factor (not in the ‘active/elated’ factor) com-
pared to the non-hypomanic group [19]. Other studies
also indicated that irritable/risk-taking symptoms might
have more relevance to bipolarity and related psycho-
pathological conditions [19, 31]. In a study of an adoles-
cent group, ‘irritable/erratic’ factor and ‘disinhibited/
stimulation-seeking’ factor of the HCL-32 were signifi-
cantly associated with behavioral and cognitive problems
that are prevalent in BDs, while ‘active/elated’ factor
negatively correlated with peer problems [31]. Partici-
pants in another adult study cohort reporting irritable/
risk-taking hypomania had more depressive symptoms,
sleep disturbances, somatic complaints, perceived stress,
and lower self-efficacy compared to those reporting ac-
tive/elated hypomania or no hypomania [35].
We applied the same analyses in the present study to
BD and two subgroups (BD1 and BD2). The HCL-32
total and sub-domains scores showed better discrimin-
ation ability in BD2 compared to BDs and BD1. Previous
manic episodes are much easier to detect than hypo-
manic episodes in patients with depressive episodes [34].
Therefore, the HCL-32 was developed to focus on the
Table 3 Analyses of the discrimination power of HCL-32 and its sub-domains in screening BDs
HCL-32 total Active/elated Irritable/risk-taking
BD1 vs Control
AUC (95 % CI) 0.56 (0.51–0.61) 0.52 (0.47–0.57) 0.67 (0.62–0.72)
optimal cut-off score >19 ≥12 >2
PPV (%) 38.87 (28.89–49.60) 29.72 (23.42–36.65) 37.96 (31.07–45.24)
NPV (%) 77.72 (72.22–81.52) 76.53 (70.50–81.86) 83.20 (77.77–87.76)
sensitivity (95 % CI) 0.32 (0.24–0.42) 0.52 (0.42–0.62) 0.65 (0.55–0.74)
specificity (95 % CI) 0.82 (0.77–0.86) 0.56 (0.50–0.62) 0.62 (0.56–0.67)
BD2 vs Control
AUC 0.64 (0.60–0.69) 0.54 (0.49–0.59) 0.75 (0.70–0.79)
optimal cut-off score >21 >11 >2
PPV (%) 53.84 (43.54–71.23) 27.20 (22.06–32.84) 37.63 (30.82–44.81)
NPV (%) 81.31 (76.95–85.17) 83.27 (76.12–88.99) 88.50 (83.60–92.36)
sensitivity (95 % CI) 0.31 (0.22–0.40) 0.76 (0.66–0.83) 0.74 (0.64–0.82)
specificity (95 % CI) 0.93 (0.90–0.96) 0.37 (0.32–0.43) 0.62 (0.56–0.67)
BDs vs Control
AUC 0.60 (0.56–0.65) 0.51 (0.47–0.56) 0.71 (0.67–0.75)
optimal cut-off score >19 >10 >2
PPV (%) 58.44 (49.66–66.83) 43.31 (38.28–48.46) 56.07 (49.94–62.07)
NPV (%) 64.57 (59.65–69.28) 63.82 (55.64–71.45) 73.99 (68.24–79.19)
sensitivity (95 % CI) 0.36 (0.30–0.43) 0.75 (0.68–0.80) 0.69 (0.62–0.75)
specificity (95 % CI) 0.82 (0.77–0.86) 0.31 (0.26–0.37) 0.62 (0.56–0.67)
Cut-off score with the highest Youden’s Index value
AUC the area under the curve of the receiver operating characteristic (ROC) curve, HCL-32 hypomania checklist 32, BD1 bipolar I disorder, BD2 bipolar II disorder,
BDs bipolar disorders, PPV positive predictive value, NPV negative predictive value
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identification of hidden hypomanic components in pa-
tients with depressive episodes in order to obtain reliable
diagnoses of BD2 and bipolar spectrum disorders [15].
The validity of the HCL-32 in the detection of BD2 and
minor BDs in patients with depressive episodes was
demonstrated in subsequent studies [6, 34]. The present
study shows that most of the items of irritable/risk-tak-
ing factor of the HCL-32 could be useful in the screen-
ing of hypomanic state of the BD2 in the non-clinical
population.
There are certain limitations to be considered in the
interpretation of the present results. First, psychiatric as-
sessments using the structured clinical interview were
not performed for the control group which could lead to
inclusion of un-diagnosed BD patients in the control
group. Second, as patients were recruited in a single psy-
chiatric unit, they could not represent BD patients in
general in terms of demographic and clinical characteris-
tics. Third, the current mood state of the patients could
have yielded a recall bias on their previous hypomanic
state assessed in the HCL-32. Last, differences in the
education level between the patients and control groups
could be an uncontrolled confounding factor.
Within the mentioned limitations, the present study is
meaningful as the first study to evaluate the clinical utility
of HCL-32 for screening BDs in non-clinical samples. Our
findings indicated that even though the HCL-32 total
score and active/elated factor score could not adequately
screen BDs from the general population, irritable/risk-tak-
ing sub-domain could be clinically useful for distinguish-
ing BDs from the control groups. Beyond its quality as a
screening instrument, future studies would be required to
explore whether the irritable/risk-taking sub-domain of
the HCL-32 might also be useful in assessing the severity
measures of the illness in the course of BD.
Conclusions
This study investigated the clinical utility of the HCL-32
for the screening of BDs in the non-clinical general
population. The HCL-32 total score and active/elated
factor score did not show adequate screening properties
for differentiating patient groups from the control group.
However, the current results suggest that items of irrit-
able/risk-taking factor could be useful in screening BDs
in the non-clinical samples. These items can be incorpo-
rated into a future screening tool of BD for the general
population.
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